Provided by Tiger Trade Technology Pte. Ltd.

Ocugen

1.39
0.0000
Post-market: 1.410.0181+1.30%19:57 EDT
Volume:2.45M
Turnover:3.41M
Market Cap:470.54M
PE:-5.45
High:1.42
Open:1.41
Low:1.37
Close:1.39
52wk High:2.73
52wk Low:1.00
Shares:338.52M
Float Shares:327.56M
Volume Ratio:0.65
T/O Rate:0.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2551
EPS(LYR):-0.2260
ROE:-660.00%
ROA:-48.44%
PB:-28.42
PE(LYR):-6.15

Loading ...

Ocugen (OCGN) Receives a Buy from Noble Financial

TIPRANKS
·
Apr 06

Assessing Ocugen (OCGN) Valuation After Strong One Year Share Price Momentum

Simply Wall St.
·
Apr 04

BUZZ-U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences

Reuters
·
Apr 02

Sector Update: Health Care Stocks Advance Pre-Bell Wednesday

MT Newswires Live
·
Apr 01

Ocugen completes dosing in GARDian3 trial

TIPRANKS
·
Apr 01

BUZZ-U.S. STOCKS ON THE MOVE-Seagate, nCino, Zymeworks

Reuters
·
Apr 01

BUZZ-Ocugen rises after finishing patient dosing in late-stage eye gene therapy trial

Reuters
·
Apr 01

Ocugen completes dosing in Phase 2/3 Stargardt gene therapy trial ahead of schedule

Reuters
·
Apr 01

Ocugen Inc. Stock Rises Tuesday, Outperforms Market

Dow Jones
·
Apr 01

Ocugen Inc. Stock Slips 6.4%, Underperforms Market

Dow Jones
·
Mar 31

Ocugen Inc. Stock Sheds 4.6%, Underperforms Market

Dow Jones
·
Mar 28

Assessing Ocugen (OCGN) Valuation After Recent Share Price Volatility And Long Term Momentum

Simply Wall St.
·
Mar 27

Canaccord Genuity Sticks to Its Buy Rating for Ocugen (OCGN)

TIPRANKS
·
Mar 26

Ocugen Inc. Stock Rises Wednesday, Outperforms Market

Dow Jones
·
Mar 26

Ocugen: Encouraging Phase 2 OCU410 Data in Geographic Atrophy Underpin Buy Rating and Long-Term Upside Potential

TIPRANKS
·
Mar 26

Is Ocugen (OCGN) Pricing Make Sense After Its Volatile Multi‑Year Share Price Swings

Simply Wall St.
·
Mar 25

Ocugen Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 25

Ocugen price target raised to $10 from $7 at H.C. Wainwright

TIPRANKS
·
Mar 25

Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday

MT Newswires Live
·
Mar 24

Ocugen Reports Positive Phase 2 Trial Data For Eye Disease Therapy

MT Newswires Live
·
Mar 24